31. |
|
|
32. |
|
|
33. |
|
|
34. |
- Rosenberg, Rutger, 1943, et al.
(författare)
-
Marine quality assessment by use of benthic species-abundance distributions: a proposed new protocol within the European Union Water Framework Directive
- 2004
-
Ingår i: Marine Pollution Bulletin. - : Elsevier BV. - 0025-326X. ; 49:9-10, s. 728-739
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of this study is to develop a new method for classification of marine benthic quality according to the European Union Water Framework Directive. Tolerance values to environmental disturbance were determined in an objective analysis for benthic species along the Swedish west coast by using 4676 samples from 257 stations. Based on a combination of the species tolerance values, abundance and diversity, a benthic quality index (BQI) was calculated for the assessment of environmental status at a particular station. The qualification of BQl was evaluated in relation to known spatial and temporal gradients of disturbance. (C) 2004 Elsevier Ltd. All rights reserved.
|
|
35. |
|
|
36. |
|
|
37. |
|
|
38. |
|
|
39. |
- Sjostrom, J, et al.
(författare)
-
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer
- 2002
-
Ingår i: European Journal of Cancer. - 1879-0852. ; 38:4, s. 535-542
-
Tidskriftsartikel (refereegranskat)abstract
- Breast cancer patients with c-erbB-2-positive tumours seem to benefit from anthracycline-based adjuvant chemotherapy. The predictive value of c-erbB-2 for taxane sensitivity is not yet clear. The purpose of this study was to assess whether c-erbB-2 expression is associated with clinical sensitivity to docetaxel (T) or sequential methotrexate and 5-fluorouracil (MF). A total of 283 patients with metastatic breast cancer were initially enrolled in a randomised multicentre trial comparing docetaxel with sequential MF in advanced breast cancer. Paraffin-embedded blocks of the primary tumour were available for 131 patients (46%). c-erbB-2 status was determined by immunohistochemistry using a polyclonal antibody to the c-erbB-2 protein. C-erbB-2 expression was scored in a semi-quantitative fashion using a 0 to 3+ scale. Staining scores 2+ or greater were considered positive, Response evaluation was performed according to World Health Organization (WHO) recommendations. Overall 54 (42%) patients had c-erbB-2-positive tumours. There was no association between treatment outcome and c-erbB-2 overexpression. The overall response rates (RR) (n = 128) among c-erbB-2 -negative and -positive patients were 35 and 44%, respectively (P=0.359). In the MF arm (n = 62), the RR was somewhat higher in the c-erbB-.2 overexpressors (33% versus 18%, P = 0. 18). In the docetaxel arm the RRs were very similar, regardless of the c-erbB-2 expression (53% versus 53%). While several studies have suggested a prognostic and putative predictive significance of c-erbB-2 overexpression in early breast cancer, the significance of c-erbB-2 expression as a predictive factor for response to various cytotoxic treatments in advanced breast cancer is still controversial. In this study, c-erbB-2 expression could not predict response to either MF or T. Thus, tumours over-expressing c-erbB-2 are not uniformly more sensitive to taxanes and c-erbB-2 expression cannot yet be applied clinically as a predictive factor for response in advanced breast cancer.
|
|
40. |
|
|